The Effect of Ursodesoxycholic Acid on Duodenal Adenomas in Familial Adenomatous Polyposis: A Prospective Randomized Placebo-Control Trial | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

The Effect of Ursodesoxycholic Acid on Duodenal Adenomas in Familial Adenomatous Polyposis: A Prospective Randomized Placebo-Control Trial

key information

source: Colorectal Disease

year: 2012

authors: Parc Y, Desaint B, Fléjou J F, Lefèvre J H, Serfaty L, Vienne A, Kotti S, Simon T, Tiret E

summary/abstract:

AIM:
Duodenal adenomas occur in about 90% of patients with familial adenomatous polyposis (FAP) and are the second cause of death of patients who have had a prophylactic proctocolectomy. Studies suggest that biliary acids have a role in the development of duodenal adenomas. The aim of this study was to evaluate the impact of ursodesoxycholic acid (UDCA) on duodenal adenoma formation in patients with FAP.

METHOD:
A randomized, double-blinded, placebo-controlled study was carried out of 71 patients (20-65 years) who already had a restorative proctocolectomy. Subjects received either 10 mg/kg of UDCA orally per day or a placebo tablet for 24 months. The Spigelman severity score was determined after duodenal axial and lateral view endoscopy at 12 and 24 months.

RESULTS:
At 2 years 55 patients had completed the entire period of treatment. At the end of the follow-up period, nine (25%) patients in the UDCA group and seven (20%) in the placebo group had a decrease in the Spigelman score (P = 0.6142). Patients receiving UDCA had no side-effects (0%) compared with four (14%) in the placebo group (P = 0.0392).

CONCLUSION:
UDCA had no effect on the development of duodenal adenomas in FAP patients (NCT: 00134758).

organization: Université Pierre et Marie Curie

DOI: 10.1111/j.1463-1318.2011.02816.x

read more full text source

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close